NHL

August 2, 2016August 2, 2016

Non-Hodgkin’s Lymphoma to Open Online Educational Series by Lymphoma Society and PlatformQ

News, Social Clips

Notwithstanding the vast expenditure of effort devoted to public education on cancer prevention, cancer remains highly unpredictable and, according to the World Health Organization (WHO), approximately 14 million new cases ... Read more

July 20, 2016July 20, 2016

Five-Year Trial Results Show Efficacy of Adcetris in Treating Hodgkin’s Lymphoma

News

Seattle Genetics and Takeda Pharmaceutical announced the publication of long-term, final results from the pivotal Phase 2 clinical trial that led to the approval of Adcetris (brentuximab vedotin) as monotherapy in patients with relapsed ... Read more

July 1, 2016July 1, 2016

Hepatitis B- and C-Positive Patients Seem to Carry Higher Risks for Non-Hodgkin’s Lymphoma, According to Study

News

In an Italian case-control study with non-Hodgkin’s lymphoma (NHL) patients, researchers confirmed an increased risk for those positive for hepatitis C virus (HCV) and hepatitis B virus (HBV). The findings ... Read more

June 20, 2016June 20, 2016

Phase 2 Study of Candidate for Refractory Indolent Non-Hodgkin Lymphoma Patients So-So

News

Infinity Pharmaceuticals recently announced that its Phase 2 clinical trial Dynamo evaluating the efficacy and safety of duvelisib in patients with refractory indolent non-Hodgkin lymphoma (iNHL) met its primary endpoint but ... Read more

June 17, 2016June 17, 2016

EU Approves Gazyvaro (obinutuzumab) as a Treatment for Advanced Follicular Lymphoma

News

Roche announced that the European Commission has approved Gazyvaro (obinutuzumab), combined with bendamustine chemotherapy, to treat follicular lymphoma patients who have failed to respond to, or whose disease progressed despite, treatment with rituximab (MabThera) or a ... Read more

May 26, 2016May 26, 2016

Therapeutic Potential of Genetically Engineered T Cells for Non-Hodgkin’s Lymphoma Patients Addressed in Phase 2 Trial

News

A novel cellular immunotherapy in which patients’ T cells are engineered to express the chimeric antigen receptor (CAR) for CD19, a cell surface protein expressed on lymphoma cells, is being ... Read more

May 16, 2016May 16, 2016

Epizyme to Present Clinical Data on NHL Treatment at ASH Lymphoma Conference

News

Epizyme, Inc., recently announced it will present four abstracts at the upcoming American Society of Hematology (ASH) Conference on Lymphoma Biology. The abstracts report data from its clinical development program of tazemetostat in patients ... Read more

May 4, 2016May 4, 2016

New NCCN Booklets Help Non-Hodgkin Lymphoma Patients Better Understand Disease, Treatments

News

This year, an estimated 72,580 people in the U.S. are expected to be diagnosed with non-Hodgkin lymphomas (NHL), making it the sixth most common cancer in both men and women, according to the American ... Read more

April 29, 2016April 29, 2016

IBC Generium Chooses Partner to Develop IgG-based Antibody as Possible Lymphoma Treatment

News

IBC Generium (also known as International Biotechnology Center Generium) has selected Goodwin Biotechnology to access, process and manufacture its immunoglobulin G (IgG)-based, bispecific antibody, GNR-047, to prepare it for testing in early clinical trials it plans to conduct in ... Read more

April 5, 2016April 5, 2016

Lymphoma Linked to Rheumatoid Factor and Disease Activity in Primary Sjögren’s Syndrome Patients

News

Predictive factors for lymphoma development in people with primary Sjögren’s syndrome include the presence of rheumatoid factor and disease activity, in addition to those factors already known, according to research titled “Rheumatoid Factor ... Read more